Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says

MT Newswires Live

Nov 01

Intellia Therapeutics (NTLA) faces heightened uncertainty after pausing patient enrollment and dosing in two Phase 3 trials of its gene-editing therapy, nex-z, BofA said Friday in a report, downgrading the company's stock and slashing its price target.

On Monday, Intellia announced it had halted trials for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy after a participant experienced elevated liver enzymes and bilirubin levels following treatment.

Nex-z, Intellia's largest potential revenue driver, "is now delayed with a potentially more complicated path to market," BofA said, lowering its estimated probability of success for both programs.

BofA downgraded its rating on Intellia to neutral from buy and cut its price target to $14 from $30.

Shares of Intellia rose 4% in recent Friday trading. The stock plunged 42% on Monday after the corporate announcement.

Price: 12.76, Change: +0.49, Percent Change: +4.04

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2580495490"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2580495490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2580495490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-01 02:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2580495490","market":"us","top_or_hot":-1,"title":"Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/NTLA\">Intellia</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NTLA) faces heightened uncertainty after pausing patient enrollment and dosing in two Phase 3 trials of its gene-editing therapy, nex-z, BofA said Friday in a report, downgrading the company's stock and slashing its price target.</p><p>On Monday, Intellia announced it had halted trials for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy after a participant experienced elevated liver enzymes and bilirubin levels following treatment.</p><p>Nex-z, Intellia's largest potential revenue driver, \"is now delayed with a potentially more complicated path to market,\" BofA said, lowering its estimated probability of success for both programs.</p><p>BofA downgraded its rating on Intellia to neutral from buy and cut its price target to $14 from $30.</p><p>Shares of Intellia rose 4% in recent Friday trading. The stock plunged 42% on Monday after the corporate announcement.</p><p>Price: 12.76, Change: +0.49, Percent Change: +4.04</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Intellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIntellia Stock Downgraded After Trial Pause Raises Safety Concerns, BofA Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-11-01 02:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/NTLA\">Intellia</a> <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (NTLA) faces heightened uncertainty after pausing patient enrollment and dosing in two Phase 3 trials of its gene-editing therapy, nex-z, BofA said Friday in a report, downgrading the company's stock and slashing its price target.</p><p>On Monday, Intellia announced it had halted trials for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy after a participant experienced elevated liver enzymes and bilirubin levels following treatment.</p><p>Nex-z, Intellia's largest potential revenue driver, \"is now delayed with a potentially more complicated path to market,\" BofA said, lowering its estimated probability of success for both programs.</p><p>BofA downgraded its rating on Intellia to neutral from buy and cut its price target to $14 from $30.</p><p>Shares of Intellia rose 4% in recent Friday trading. The stock plunged 42% on Monday after the corporate announcement.</p><p>Price: 12.76, Change: +0.49, Percent Change: +4.04</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2580495490","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2580495490","pubTimestamp":1761934402,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Intellia Therapeutics (NTLA) faces heightened uncertainty after pausing patient enrollment and dosing in two Phase 3 trials of its gene-editing therapy, nex-z, BofA said Friday in a report, downgradin","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1861559042.SGD":"日兴方舟颠覆性创新基金B SGD","BK4585":"ETF&股票定投概念","NTLA":"Intellia Therapeutics Inc","LU1861558580.USD":"日兴方舟颠覆性创新基金B","BK4588":"碎股","BK4556":"基因编辑","BK4535":"淡马锡持仓"},"translate_title":"美国银行表示，审判暂停引发安全担忧后Intellia股票评级被下调","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics (NTLA) faces heightened uncertainty after pausing patient enrollment and dosing in two Phase 3 trials of its gene-editing therapy, nex-z, BofA said Friday in a report, downgrading the company's stock and slashing its price target.On Monday, Intellia announced it had halted trials for patients with transthyretin amyloidosis with cardiomyopathy and polyneuropathy after a participant experienced elevated liver enzymes and bilirubin levels following treatment.Nex-z, Intellia's largest potential revenue driver, \"is now delayed with a potentially more complicated path to market,\" BofA said, lowering its estimated probability of success for both programs.BofA downgraded its rating on Intellia to neutral from buy and cut its price target to $14 from $30.Shares of Intellia rose 4% in recent Friday trading. The stock plunged 42% on Monday after the corporate announcement.Price: 12.76, Change: +0.49, Percent Change: +4.04","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}